fda compounding semaglutide enforcement news november 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns – Partnership for Safe Medicines FDA and Novo Nordisk Warned

The Precision Peptide Genetic Test reveals predispositions in peptide signaling pathways relevant to GLP-1 mechanism and metabolic adaptation

The vendor operates within the research peptide marketplace serving individuals exploring compounds like retatrutide , the novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously for metabolic research applications

Individuals with Obesity or Overweight Concerns GLP-1 therapy is particularly effective for individuals with a BMI indicating obesity or overweight status

Starting dose suggestions for research No established dosing protocols exist for intranasal retatrutide